Project Grant R01DA063159
Award Date
5/15/25
Completion Date
3/31/30
Dollars Obligated
$687K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $234,000.00 to Georgetown University to research the impact of opioids on HIV transcription and latency. The goal is to understand how opioids may enhance HIV proviral transcription and reactivate the latent viral reservoir in the brain. The researchers will utilize a novel dual fluorescent and bioluminescent HIV virus to visualize active proviral...
This $804,728 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to investigate the role of the cysteinyl leukotriene-cysteinyl leukotriene receptor 1 (CYSLT-CYSLTR1) axis in methamphetamine-induced promotion of HIV-1 persistence and brain injury, despite combination antiretroviral therapy (cART). The key research objectives are to: 1) Determine how methamphetamine engages the CYSLT-CYSLTR1...
This federal Project Grant award of $157,568.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to elucidate the corticolimbic circuit and neuroimmune mechanisms underlying the dysregulation of reward-seeking behavior in the context of comorbid HIV and cocaine use disorders (CUDs). The primary objectives are to: 1) use circuit-specific optogenetic stimulation of the infralimbic cortex to the nucleus accumbens shell pathway to...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $2,312,085 to Boston University Medical Campus to investigate the molecular mechanisms linking HIV infection and opioid use disorder (OUD) in the development of HIV-associated neurocognitive disorders (HAND). The research aims to delineate how HIV infection activates the inflammasome in human microglia and how opioid exposure can degrade...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $983,672 to The Regents of the University of California, San Francisco (UCSF) to conduct innovative spatial characterization of the central nervous system (CNS) HIV reservoir and associated host cellular interactions in people with HIV (PWH). The key objectives are to: 1) Implement advanced spatial multi-omic assays to analyze the localization,...
The National Institute on Drug Abuse (NIDA) awarded Emory University a $1,481,760 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to study the impact of methamphetamine use on immune dysfunction and HIV reservoir activation in people living with HIV on antiretroviral therapy (ART). The key objectives are to determine how methamphetamine induces inflammasome activation, metabolic changes, and epigenetic modifications that promote immune dysfunction in T cells and...
This $4,920,000 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support a randomized controlled trial to investigate the feasibility, acceptability, and preliminary effectiveness of using long-acting injectable naltrexone as a preventive measure for opioid overdose in individuals using stimulants and living with or at risk of HIV. The key objectives are to: 1) assess the use of naltrexone for...
This federal Project Grant award of $1,465,275 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting research at the University of Alabama at Birmingham (UAB) to investigate the role of HIV proteins in psychostimulant abuse. The key objectives of this 5-year project, which commenced on May 1, 2025, are to examine how the HIV trans-activator of transcription (Tat) protein can alter the interactions between the dopamine...
This federal Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of novel NLRP3 inhibitors to address HIV-associated neuroinflammation in individuals with cocaine use. The $263,119 award, with a period of performance from August 1, 2024 to July 31, 2026, aims to computationally design, synthesize, and screen new NLRP3 inhibitor analogues. The project will evaluate the inhibitors'...
This $1,381,500 Project Grant was awarded on September 1, 2024 by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The goal of the research is to explore the role of sex differences in the establishment and maintenance of HIV/SIV reservoirs in the context of opioid use. The research will utilize a rhesus macaque model to systematically document differences in the location, abundance, and persistence of viral reservoirs between males...